Ann Rehabil Med.  2016 Dec;40(6):1144-1148. 10.5535/arm.2016.40.6.1144.

Acute Cerebral Infarction as a Rare Thrombotic Event in Myelodysplastic Syndrome: A Case Report

• Bae HW
• Kim HD
• Choi SW
• Han N
• Eom MJ

• KMID: 2371350
• DOI: http://doi.org/10.5535/arm.2016.40.6.1144

Abstract

Myelodysplastic syndrome (MDS) is a bone marrow failure syndrome characterized by cytopenia that results in high risks of infection and bleeding. However, there are few reports of cerebral infarction in MDS. We reported a 72-year-old female with MDS who developed acute cerebral infarction. Clinical history of the patient revealed no definite risk factors for stroke except diabetes mellitus and dyslipidemia that was well controlled. This case represented the rare occurrence of arterial thrombosis causing acute cerebral infarction in MDS, which may be due to complex chromosomal abnormality and inflammatory processes.

Keyword

Myelodysplastic syndromes; Stroke; Thrombosis

MeSH Terms

Aged
Bone Marrow
Cerebral Infarction*
Chromosome Aberrations
Diabetes Mellitus
Dyslipidemias
Female
Hemorrhage
Humans
Myelodysplastic Syndromes*
Risk Factors
Stroke
Thrombosis

Figure

• 

  Fig. 1 Acute cerebral infarction in the left cerebral deep white matter showing (A, B) high signal intensity on diffusion-weighted images and (C, D) low signal intensity on apparent diffusion coefficient map of brain magnetic resonance imaging.

• 

  Fig. 2 Images of brain and neck magnetic resonance angiography. (A) A segmental signal loss at the left proximal M1 branch (arrow) suggesting severe stenosis and/or acute thrombosis. (B) Common carotid artery, internal carotid artery, basilar artery, and vertebral artery show no abnormal vascular finding.

• 

  Fig. 3 Perfusion magnetic resonance images of brain. Abnormal perfusion with delayed mean transit time at left deep white matter.

Reference

1. Bennett JM, Kouides PA, Forman SJ. The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002). Int J Hematol. 2002; 76(Suppl 2):228–238. PMID: 12430930.

2. Yang X, Brandenburg NA, Freeman J, Salomon ML, Zeldis JB, Knight RD, et al. Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques. Clin Drug Investig. 2009; 29:161–171.

3. Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 2012; 97:15–20. PMID: 22102702.

4. DailyMed. VIDAZA: azacitidine injection, powder, lyophilized, for solution [Internet]. Maryland: US National Library of Medicine;c2016. cited 2016 Nov 12. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3495a71a-cc04-4776-851f-f185956f32af.

5. American Diabetes Association. Older adults. Diabetes Care. 2016; 39(Suppl 1):S81–S85. PMID: 26696686.

6. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke. 1994; 25:40–43. PMID: 8266381.

7. Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis: Behcet's syndrome. Leuk Lymphoma. 2001; 42:115–121. PMID: 11699198.

8. Hsu HC, Lee YM, Tsai WH, Jiang ML, Ho CH, Ho CK, et al. Circulating levels of thrombopoietic and inflammatory cytokines in patients with acute myeloblastic leukemia and myelodysplastic syndrome. Oncology. 2002; 63:64–69. PMID: 12187073.

9. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood. 2004; 104:4210–4218. PMID: 15315976.